Russia (bbabo.net), - Permission to conduct clinical trials of a drug against coronavirus based on monoclonal antibodies, developed by specialists from the Gamaleya Research Center for Epidemiology and Microbiology, should be received in the near future.

This was told by the director of the center Alexander Gintsburg. According to him, a package of documents for obtaining permission for research has already been submitted. "As far as I know, permission should be received in the near future," RIA Novosti quotes.

Recall that in December it was reported that a drug for the treatment of coronavirus based on monoclonal antibodies is also effective against the Omicron strain. Gunzburg announced clinical trials in the new year and noted that they would last three months.

bbabo.Net